A federal appeals court panel on Thursday heard
The case is before the US Court of Appeals for the Eighth Circuit after the drugmaker failed to show it would suffer harm under Missouri’s law (SB 751) in the US District Court for the Western District of Missouri in February 2025, or that it was likely to win its constitutional challenge against the law on its merits, ...